VALBIOTIS expands its innovation capacity with its new Discovery and Preclinical Research platform.
Positive results from Phase I/II clinical study on LpD64September 11th 2018
VALBIOTIS announces positive results from its Phase I/II clinical study conducted on LpD64 in obese subjects
Appointment of Pascal SIRVENT to the Board of Directors of VALBIOTISAugust 30th 2018
VALBIOTIS strengthens its Board of Directors and announces the appointment of Pascal SIRVENT.
Half-year report of the liquidity contract – July 2018July 17th 2018
VALBIOTIS presents the half-year report of its liquidity contract (in French)